BR112022005193A2 - Composto de piridona fundido, método de preparação do mesmo e uso do mesmo - Google Patents

Composto de piridona fundido, método de preparação do mesmo e uso do mesmo

Info

Publication number
BR112022005193A2
BR112022005193A2 BR112022005193A BR112022005193A BR112022005193A2 BR 112022005193 A2 BR112022005193 A2 BR 112022005193A2 BR 112022005193 A BR112022005193 A BR 112022005193A BR 112022005193 A BR112022005193 A BR 112022005193A BR 112022005193 A2 BR112022005193 A2 BR 112022005193A2
Authority
BR
Brazil
Prior art keywords
preparing
molted
compound
pyridone compound
pyridone
Prior art date
Application number
BR112022005193A
Other languages
English (en)
Inventor
Guo Shuchun
Fan Jun
Liu Yang
Bao Fang
Peng Jianbiao
Guo Haibing
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of BR112022005193A2 publication Critical patent/BR112022005193A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTO DE PIRIDONA FUNDIDO, MÉTODO DE PREPARAÇÃO DO MESMO E USO DO MESMO. São divulgados na presente invenção um composto de piridona fundido e um método de preparação para o mesmo e uso do mesmo. Especificamente, a presente invenção divulga um composto de fórmula (I-B), um isômero óptico do mesmo e um sal farmaceuticamente aceitável do mesmo, e o uso do composto como um inibidor de KRAS.
BR112022005193A 2019-09-20 2020-09-21 Composto de piridona fundido, método de preparação do mesmo e uso do mesmo BR112022005193A2 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN202010054188 2020-01-17
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CN202010306926 2020-04-17
CN202010367694 2020-04-30
CN202010967317 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112022005193A2 true BR112022005193A2 (pt) 2022-08-16

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005193A BR112022005193A2 (pt) 2019-09-20 2020-09-21 Composto de piridona fundido, método de preparação do mesmo e uso do mesmo

Country Status (14)

Country Link
US (1) US20220389029A1 (pt)
EP (1) EP4043464A4 (pt)
JP (1) JP2022549171A (pt)
KR (1) KR20220086573A (pt)
CN (2) CN116947885A (pt)
AU (1) AU2020350745A1 (pt)
BR (1) BR112022005193A2 (pt)
CA (1) CA3155066A1 (pt)
CL (1) CL2022000666A1 (pt)
CO (1) CO2022004686A2 (pt)
IL (1) IL291467A (pt)
MX (1) MX2022003401A (pt)
TW (1) TWI761961B (pt)
WO (1) WO2021052499A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
AU2020337938A1 (en) 2019-08-29 2022-03-17 Array Biopharma Inc. KRas G12D inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US20230084095A1 (en) * 2019-10-30 2023-03-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
WO2021197499A1 (zh) * 2020-04-03 2021-10-07 南京明德新药研发有限公司 八氢吡嗪并二氮杂萘啶二酮类化生物
CN116406363A (zh) * 2020-08-21 2023-07-07 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
CN116670136A (zh) * 2020-12-31 2023-08-29 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
CN116964056A (zh) * 2021-03-25 2023-10-27 上海济煜医药科技有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
WO2022198904A1 (zh) * 2021-03-26 2022-09-29 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
CN117242079A (zh) * 2021-07-23 2023-12-15 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN117222654A (zh) * 2021-09-06 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
TW202327593A (zh) * 2021-12-24 2023-07-16 大陸商勁方醫藥科技(上海)有限公司 Kras抑制劑的多晶型物及其製備方法和用途
CN116327956A (zh) * 2022-04-01 2023-06-27 劲方医药科技(上海)有限公司 药物组合物、其用途及癌症的治疗方法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014331794C1 (en) * 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
CA2981530A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) * 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
WO2017100546A1 (en) * 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2018142365A1 (en) * 2017-02-03 2018-08-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019110751A1 (en) * 2017-12-08 2019-06-13 Astrazeneca Ab Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
WO2019141250A1 (zh) * 2018-01-19 2019-07-25 南京明德新药研发股份有限公司 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
US11090304B2 (en) * 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CN111484477B (zh) * 2019-01-29 2022-07-08 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
US20230084095A1 (en) * 2019-10-30 2023-03-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

Also Published As

Publication number Publication date
TW202126654A (zh) 2021-07-16
TWI761961B (zh) 2022-04-21
KR20220086573A (ko) 2022-06-23
EP4043464A1 (en) 2022-08-17
US20220389029A1 (en) 2022-12-08
AU2020350745A1 (en) 2022-04-07
CN114728968A (zh) 2022-07-08
CN116947885A (zh) 2023-10-27
CO2022004686A2 (es) 2022-07-08
CA3155066A1 (en) 2021-03-25
MX2022003401A (es) 2022-07-13
IL291467A (en) 2022-05-01
EP4043464A4 (en) 2023-10-04
CL2022000666A1 (es) 2022-10-14
WO2021052499A1 (zh) 2021-03-25
JP2022549171A (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
BR112022005193A2 (pt) Composto de piridona fundido, método de preparação do mesmo e uso do mesmo
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
BR112022009557A2 (pt) Inibidores de kras g12c
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2017002090A1 (es) Inhibidores selectivos de bace1
CL2017002908A1 (es) Amidas heterocíclicas como inhibidores de quinasa.
CL2017002883A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
CR20190124A (es) Inhibidores de ssao de aminopirimidina
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CU20200080A7 (es) Kit que comprende un inhibidor de lats para el suministro ocular
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CL2018001067A1 (es) Compuesto piranodipiridínico.
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина